Plasminogen activator inhibitor type 1 gene polymorphism and sepsis

Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S453-8. doi: 10.1086/431996.

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) is a 50-kilodalton glycoprotein of the serine protease inhibitor family. The primary role of PAI-1 in vivo is the inhibition of both tissue- and urokinase-type plasminogen activators. In addition to this function, PAI-1 acts as an acute-phase protein during acute inflammation. PAI-1 is a pivotal player in the pathogenesis of sepsis, a complex clinical syndrome that results from a systemic inflammatory response. In patients with sepsis, the levels of PAI-1 are positively related to poor outcome, increased severity of disease, and increased levels of various cytokines, acute-phase proteins, and coagulation parameters. The 4G/5G insertion/deletion promoter polymorphism, which leads to differences in PAI-1 production, has been demonstrated to affect the risk of developing severe complications and dying from sepsis during meningococcal infection and multiple trauma.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Drug Delivery Systems
  • Gene Expression Regulation
  • Humans
  • Inflammation / genetics*
  • Inflammation / immunology
  • Meningococcal Infections / genetics
  • Meningococcal Infections / immunology
  • Plasminogen Activator Inhibitor 1 / biosynthesis
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Plasminogen Activator Inhibitor 1 / immunology
  • Polymorphism, Genetic
  • Sepsis / etiology
  • Sepsis / genetics*
  • Sepsis / immunology
  • Severity of Illness Index

Substances

  • Plasminogen Activator Inhibitor 1